-
PBS Liposomes: Evidence, Controls, and Limits
2026-10-07
A source-grounded overview of what PBS Liposomes are intended to control, how to interpret them beside clodronate liposomes, and where the available evidence remains limited.
-
1-Myristoylglycerophosphocholine in Lipid Signaling
2026-10-06
A source-grounded overview of 1-myristoylglycerophosphocholine and 14:0 Lyso-PC research, including pulmonary fibrosis findings, conceptual applications, evidence strength, and important limitations.
-
3D Gold Nanocluster Arrays for Reproducible SERS
2026-10-05
The reference study presents a polymer pen lithography strategy for building ordered three-dimensional gold nanocluster arrays on patterned polyethylenimine structures. It reports a SERS enhancement factor of 1.67 × 10^7 and a relative standard deviation below 4.73%, while showing that array architecture can be regulated through lithographic pattern design.
-
Epigenetic MCL-1 Targeting in Glioblastoma
2026-10-05
The reference study identifies a super-enhancer-associated Mcl-1 dependency in glioblastoma and shows that epigenetic suppression of Mcl-1 can cooperate with BCL-2/BCL-XL inhibition to promote apoptotic cell death. Its combined genomic, cellular, mechanistic, and patient-derived xenograft evidence supports a preclinical synthetic-lethality model, while leaving important questions about tumor heterogeneity, blood–brain barrier exposure, and clinical safety unresolved.
-
CP-673451 and PDGFR Signaling in Cancer Research
2026-10-04
CP-673451 is described by APExBIO as a selective PDGFRα/β inhibitor with preclinical activity in receptor-signaling and angiogenesis models. Peer-reviewed evidence separately indicates that ATRX-deficient high-grade glioma cells can be more sensitive to selected RTK and PDGFR inhibitors, but the supplied evidence does not establish clinical efficacy or prove that CP-673451 itself accounts for those findings.
-
5-Methyl-CTP in mRNA Research: Evidence and Limits
2026-10-03
5-Methyl-CTP is a 5-methyl modified cytidine triphosphate discussed as a substrate for modified mRNA synthesis. This overview separates supplier claims about enhanced mRNA stability and translation from published in vivo evidence, including a hemagglutinin mRNA–lipid nanoparticle vaccine study in lactating dairy cows. It explains the research context, conceptual applications, evidence gaps, provenance, and limits on attributing vaccine performance to any single nucleotide modification.
-
JXE-23 Induces Protective Autophagy in HCC Cells
2026-10-02
The 2024 reference study identifies JXE-23, a pimarane-type diterpene from Aleuritopteris albofusca, as a selective inhibitor of HepG2 hepatocellular carcinoma cell growth. Its combination of G2/M arrest, migration suppression, and protective autophagy links the CIP2A/p-AKT/c-Myc axis to a potentially exploitable survival response.
-
Triiodothyronine T3 in Metabolic Assays
2026-10-01
Triiodothyronine (T3) enables controlled thyroid hormone receptor activation alongside metabolic and gene-expression readouts. This practical guide shows how to use T3 as a phenotyping variable when evaluating oligodendrocyte models and spatially concentrated adenine base-editing workflows, while keeping formulation, dosing, and interpretation reproducible.
-
GW 6471 for Reliable PPARα Assays
2026-10-01
Learn how GW 6471 (SKU B7797) can strengthen PPARα-focused cell viability, proliferation, and cytotoxicity workflows through controlled dosing, vehicle matching, and mechanism-aware interpretation. The article connects product specifications with recent PFHxS hepatotoxicity evidence while clarifying practical limitations across cell and zebrafish models.
-
Fluo-4 AM in Podocyte Calcium Signaling
2026-09-30
Discover how Fluo-4 AM can turn calcium flux into a mechanistic readout for podocyte injury and diabetic nephropathy research. This guide connects probe design, assay controls, and the GPR107–AT1R–Ca2+ pathway to more informative calcium signaling experiments.
-
3D Au Nanocluster Arrays by Polymer Pen Lithography
2026-09-30
The reference study integrates polymer pen lithography with electrostatic nanoparticle assembly to produce ordered three-dimensional gold nanocluster arrays for SERS. Its central contribution is structural programmability: adjusting lithographic pattern parameters regulates array architecture while delivering a reported enhancement factor of 1.67 × 107 and intersubstrate reproducibility with RSD below 4.73%.
-
Isoprinosine Workflows for HSV-1 Research
2026-09-29
Build a mechanistically resolved antiviral workflow with Isoprinosine, combining viral replication, host-response, viability, and nuclear-egress readouts. The approach separates immunomodulatory activity from direct effects on HSV-1 trafficking and uses CLCC1-focused controls to improve interpretation.
-
Esflurbiprofen and SERT–nNOS: Fast-Onset Antidepressant
2026-09-29
The reference study identifies esflurbiprofen as a candidate fast-onset antidepressant that disrupts the SERT–nNOS complex in the dorsal raphe nucleus. By combining mBRET-based screening, stress-model pharmacology, behavioral testing, and rs-fMRI, the authors connect this molecular interaction to altered serotonergic feedback and improved depressive-like behaviors in mice.
-
Angiotensin II: Practical Assay and Model Guidance
2026-09-28
Angiotensin II (A1042) provides a defined octapeptide stimulus for experiments on receptor-linked vascular responses, oxidase activity, hypertension mechanisms, and cardiovascular remodeling. This guide outlines preparation and model-use considerations; the reagent is for research workflows only, not diagnostic or medical use.
-
Senescence, Apoptosis, and the Case for Better Controls
2026-09-27
Chemotherapy can leave behind senescent tumor cells that resist apoptosis yet contribute to relapse. This article connects senolytic research with practical caspase-inhibition controls, explaining where Q-VD-OPh can clarify mechanism—and where it can confound translation.